Our Science
We understand that only the most dedicated researchers, world-class facilities, and highest standards in science, quality, and ethics, will deliver the results we need for our patients, and help fulfill more unmet needs. That’s why over the past five years we’ve reinvested approximately 35% of our revenues into and research and development. Our R&D capabilities are recognized worldwide, from pre-clinical research through all phases of clinical development with proven expertise and focus in cancer care and rare diseases.
Pipeline
Our growing pipeline includes first-in-class therapies aimed at providing new solutions where no options currently exist, with a goal to help lift the burden of cancer and other unmet needs for patients.
Late Phase Development
We currently have an active pipeline of new cancer care and rare disease products in various stages of development, including compounds in Phase III clinical development.
Investing in research
Creating an attractive and fulfilling working environment that offers employees opportunities for career advancement, contributes positively to employee satisfaction, which in turn benefits the company. AMPL reinvests approximately 35 percent of revenues generated into R&D.
